Atyr Pharma Inc. (NASDAQ:LIFE) – Equities research analysts at William Blair boosted their FY2016 earnings estimates for Atyr Pharma in a research report issued on Tuesday. William Blair analyst Y. Xu now anticipates that the firm will post earnings per share of ($2.53) for the year, up from their previous estimate of ($2.65). William Blair also issued estimates for Atyr Pharma’s Q4 2016 earnings at ($0.61) EPS, FY2017 earnings at ($2.74) EPS and FY2018 earnings at ($3.88) EPS.

Atyr Pharma (NASDAQ:LIFE) last issued its quarterly earnings data on Monday, November 14th. The company reported ($0.58) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.67) by $0.09.

LIFE has been the subject of a number of other research reports. BMO Capital Markets set a $8.00 target price on shares of Atyr Pharma and gave the stock a “hold” rating in a research report on Thursday, October 6th. Citigroup Inc. lifted their target price on shares of Atyr Pharma from $3.00 to $4.00 and gave the stock a “neutral” rating in a research report on Tuesday, August 16th. Zacks Investment Research downgraded shares of Atyr Pharma from a “buy” rating to a “hold” rating in a research report on Wednesday, October 12th. Finally, JPMorgan Chase & Co. cut their target price on shares of Atyr Pharma from $15.00 to $10.00 and set an “overweight” rating for the company in a research report on Thursday, August 11th. Three analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. The company presently has a consensus rating of “Hold” and an average price target of $6.50.

Shares of Atyr Pharma (NASDAQ:LIFE) opened at 3.60 on Thursday. The stock’s market cap is $85.38 million. The company has a 50 day moving average price of $2.97 and a 200-day moving average price of $3.06. Atyr Pharma has a 12 month low of $2.48 and a 12 month high of $10.93.

Large investors have recently modified their holdings of the stock. GSA Capital Partners LLP acquired a new stake in shares of Atyr Pharma during the second quarter worth about $101,000. A.R.T. Advisors LLC increased its stake in shares of Atyr Pharma by 88.8% in the second quarter. A.R.T. Advisors LLC now owns 39,143 shares of the company’s stock worth $108,000 after buying an additional 18,410 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. increased its stake in shares of Atyr Pharma by 199.2% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 35,600 shares of the company’s stock worth $113,000 after buying an additional 23,700 shares during the last quarter. Bridgeway Capital Management Inc. acquired a new stake in shares of Atyr Pharma during the second quarter worth about $133,000. Finally, Jackson Park Capital LLC acquired a new stake in shares of Atyr Pharma during the second quarter worth about $183,000. 44.63% of the stock is owned by hedge funds and other institutional investors.

Atyr Pharma Company Profile

aTyr Pharma, Inc is a clinical-stage biotherapeutics company. The Company is engaged in the discovery and clinical development of medicines for patients suffering from severe, rare diseases using its Physiocrine biology, a discovered set of physiological modulators. The Company focuses on the development of Physiocrine-based therapeutics for the treatment of rare diseases, including facioscapulohumeral muscular dystrophy (FSHD) and limb-girdle muscular dystrophy (LGMD) 2B.

5 Day Chart for NASDAQ:LIFE

Receive News & Stock Ratings for Atyr Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atyr Pharma Inc. and related stocks with our FREE daily email newsletter.